Last week →  The hemp cliff just moved to December 11 — with a catch

The court declined to blink. Virginia's 2 mg cap is now the law.

On Friday afternoon, U.S. District Judge Robert S. Ballou denied the temporary restraining order and preliminary injunction that seven hemp businesses had hoped would stop Virginia's hemp law at the door. "It is not the role of this Court to second-guess the Virginia legislature in setting an effective date," he wrote — and at midnight Saturday, the strictest hemp cap in the country took effect. Products over 2 milligrams of total THC per package are now unsellable in the Commonwealth, the 25:1 CBD-to-THC exemption is gone, and the attorney general's new Regulated Products Enforcement Unit is on duty. The constitutional case continues, but only on the slow track: emergency relief is dead, and shelves changed this weekend. For operators everywhere, Virginia just answered a question hanging over the fall — whether courts will pause short-runway hemp recriminalization while the merits get argued. The first data point says no. The compliance countdown, now concluded →

Why it matters: Nothing moved this week because nothing could: the House is out until September, and the Senate's December 11 delay is frozen until it returns. Opponents are expected to try stripping the delay language on the floor, and the September 30 funding deadline guarantees the fight happens fast. Planning posture is unchanged — November 12 is still the law until a reconciled bill passes.

The week's noise was positional: Sen. Ted Cruz backed the delay's structure (synthetics banned on time, natural products extended), Rep. Andy Harris blasted the White House's role, and Sen. Rand Paul argued it is no "more moral to take a Percocet than it is to take a hemp gummy." Meanwhile Reps. Beth Van Duyne (R-TX) and Greg Landsman (D-OH) filed a bipartisan bill to keep hemp THC drinks legal under an alcohol-style three-tier system — and alcohol retailer and wholesaler groups endorsed it within days.

Why it matters: This is the agency's litigation position landing exactly where the statute is headed: commercially produced HHC is a synthetic, Schedule I substance in DEA's view — and the November 12 synthetic-cannabinoid carve-out applies even if Congress delays everything else to December 11. For HHC product lines, the December extension never existed. Inventory decisions should treat November 12 as final. Talk to your counsel.

In a brief filed this week, DEA argued a hemp company cannot challenge the agency's stance that hexahydrocannabinol — typically made by hydrogenating hemp-derived THC — is a banned Schedule I substance rather than 2018 Farm Bill hemp. A court has not yet ruled on the position; details of the docket are still emerging.

Why it matters: Today, Monday August 17, is the deadline for post-hearing briefs in the DEA's expedited proceeding on rescheduling all cannabis. Once the closing arguments and transcript corrections land, the record closes and the Chief ALJ's recommended decision is the next event — the document that will frame the final rule and the inevitable appeals. Keep §280E relief unbooked until a final rule survives review. Talk to your counsel.

The expedited hearing ran June 29 through mid-July; the April 23 final order moving state-legal medical cannabis and FDA-approved products to Schedule III remains in effect while everything else awaits the recommended decision. No timetable for that decision has been set.

Why it matters: Most conventional delta-8, full-spectrum CBD and hemp THC beverage SKUs exceed 2 mg total THC per package — meaning the bulk of Virginia's intoxicating-hemp retail assortment became unsellable Saturday. Sell-through windows are over; remaining moves are re-formulation to ≤2 mg, out-of-state inventory transfer where lawful, or exit. Shipping into Virginia now carries the same exposure — re-check carrier and fulfillment policies.

Judge Ballou's Aug 14 opinion denied emergency relief but left the businesses' Fifth and Fourteenth Amendment claims alive on the merits — Nova Hemp and District Hemp Botanicals are among the plaintiffs pressing on. No merits schedule has been published; details still emerging.

Why it matters: Medical cannabis in Illinois is taxed far below adult-use, so dual authorization is a margin play with a patient-access upside. Adult-use retailers that add the medical line can serve cardholders at the lower rate and capture a customer segment that has been drifting to neighboring markets. The application window is open now — first movers get the patient loyalty.

The Illinois Department of Financial and Professional Regulation posted the new form this week allowing licensed recreational dispensaries to apply for authorization to sell medical cannabis alongside adult-use product.

Why it matters: The country's fourth-largest city may vote to make misdemeanor possession its police department's lowest enforcement priority — in the same state that recriminalized delta-8 as a felony three weeks ago. The gap between Texas state hemp policy and big-city enforcement reality keeps widening, and operators navigating both should not mistake local deprioritization for legality.

Houston City Council cleared the measure for the November ballot this week; if approved by voters, it would formalize deprioritization of misdemeanor marijuana possession arrests citywide.

Why it matters: Ukraine legalized medical cannabis in 2024 but the market has been starved of registered products. Allowing importation of medicine samples for quality verification is the unglamorous plumbing that registration pipelines need — and a signal to European producers that the registration route into a 35-million-person medical market is inching open.

Ukraine's Cabinet of Ministers is considering a proposal to permit the import of samples of cannabis-containing medicines for quality-control testing, per reporting this week. Adoption timing is not yet set; details still emerging.

A quiet week on the international desk — fuller coverage resumes as material lands.

DEA's court filing makes this the week to understand exactly where HHC sits. Our new guide walks the chemistry, the drug-test reality, and the legal line that matters: why the November 12 synthetic carve-out reaches HHC no matter what Congress does to the rest of the hemp ban. Read the summary →